EUCTR2014-001295-65-IT进行中（未招募）1 期
A phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, multi-dose and multi-injection, parallel groups study to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (ova-Treg)) in patients with active refractory Crohn’s Disease (Crohn’s And Treg Study: CATS29) - CATS29
TxCell0 个研究点目标入组 200 人开始时间: 2014年11月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At the screening visit (V1):
- •1) Willing and able to provide written informed consent (IC);
- •2) Male or Female aged between 18 and 70 (inclusive) years of age;
- •3) Crohn's Disease diagnosis defined as patients with medical history of signs, symptoms and biological evidence of active bowel inflammation: Documented endoscopic evidence of Crohn's diagnosis at least 1 year prior to V1 (an endoscopy will be perform if the one available has more than 1 year at V1);
- •4) Elevated High sensitive C-reactive protein (hs-CRP) > 10 mg/L at V1;
- •5) Calprotectin = 250 µg/g;
- •6) Failure or intolerance to conventional treatments including corticosteroid, immunosuppressant and at least one biologic; and had not responded (primarily failure) or responded and then lost response completely (no response or need to increase the dose / secondary failure) or were intolerant to this therapy at a dose indicated for CD (Refer to Appendix 17.6 for the definition of refractoriness);
- •7) Documented CDAI (Crohn's Disease Activity Index) = 250 at V1 or within the past 3 months prior to V1;
- •8) Total white cell count = 4.0.10^9 / L;
- •9) Platelets between 150.10^9 and 600.10^9 / L (included);
- •10) Hemoglobin > 8.5 g/dL;
- •11) Full blood count (FBC) and biochemistry without any clinically significant abnormalities except if CD-related, at Investigator's discretion;
- •12) Normal, or no clinically significant abnormality in the electrocardiogram (ECG) at Investigator's discretion;
- •13) Patients willing and able to observe an intake of ovalbumin through the ingestion of a meringue daily after the first administration until the end of the Double-blind phase and during the OL-phase if the patient receives additional administration;
- •At the Visit 3 (week-4):
- •1) CDAI = 250;
- •2) Evidence of inflammation by an elevated hs-CRP value (> 5 mg/L) OR endoscopic / MRI evidence of local intestinal inflammation, OR elevated calprotectin (= 250µg/g) to be confirmed before V4 (first administration);
- •Between visit 8 (week14) and visit 9 (week16):
- •1) Upon Investigator recommendation, patient qualification will be based on acceptable safety and tolerability profile of the IMP before continuing to receive intravenous administrations of Ovasave at a dose of 10^6 cells.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 185
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1) Current or recent history (12 preceding months before V1) of major organ or system failure or condition, acute or chronic that in the opinion of the Investigator should preclude enrolment, except Crohn’s Disease;
- •2) Current or previous history of malignancy except a local basal cell carcinoma without metastases;
- •3) First degree family or personal history of clinically significant venous, arterial or pulmonary thromboembolism events;
- •4) History of thrombocytosis over 600.10^9 / L in the previous 12 months prior to V1;
- •5) History of major immune deficiency disorder, except Crohn’s Disease;
- •6) Concomitant clinically active infection at V1 or V2 or V3 or V4 or V7 or V9 CATS29-OL or V11 CATS29-OL;
- •7) History of intestinal resection or intra-abdominal surgery within 6 months prior to V1;
- •8) Have complication of Crohn’s Disease such as strictures, stenosis, short gut syndrome, or any other manifestation that might require surgery, could preclude the use of CDAI to assess response to therapy, or would possibly confound the evaluation of benefit from treatment with Ovasave;
- •9) Patients with intestinal functional fibrotic structuring responsible for the patient’s symptoms or previous major Gastro Intestinal (GI) resection;
- •10) Patients with short bowel syndrome or with less than 1.5 m of small bowel;
- •11) Presence of actively draining fistula at V3 or V4;
- •12) Concomitant abdominal or anal undrained abscess at V3 or V4;
- •13) History of documented hypersensitivity or intolerance to chicken eggs;
- •14) Parenteral nutrition if not compatible with the meringue intake;
- •15) History of known hypersensitivity or intolerance to any component of the IMP (Refer to Appendix 17.7 of the Protocol for the composition of the Drug Product);
- •16) Patients with ileostomia or colostomy;
- •17) History of tuberculosis (TB) except if documentation of adequate compliance to treatment is provided,
- •18) Gamma immunoglobulinaemia < 6 g/L at Screening visit (V1) or Pre-entry visit (V3) or any signs or history of major immune deficiency disorder;
- •19) Recent history of contamination by the Epstein-Barr virus (EBV), Cytomegalovirus (CMV) and/or toxoplasma within 6 months prior to V1;
- •20) History of human immunodeficiency virus (HIV);
- •21) Females of childbearing potential who are either pregnant, breast-feeding or without the use of birth control. Female patients of child-bearing potential must have a negative pregnancy test at screening and must agree to use an acceptable method of birth control with a low failure rate (i.e. less than 1% per year) in a consistent and correct manner for the whole duration of the study treatment period and during the 3 months following the end of the study treatment period (V13/week 32). Abstinence, oral birth control pills administered for at least 2 monthly cycles prior to study drug administration, a contraceptive vaginal ring (e.g. NuvaRing or equivalent) or a contraceptive transdermal patch (e.g. EVRA or equivalent) administered for at least 2 monthly cycles prior to study drug administration, an IUD, or medroxyprogesterone acetate administered intramuscularly or a subcutaneous implant of etonogestrel (Implanon or equivalent) for a minimum of one month prior to study drug administration are acceptable methods of birth control for inclusion into the study. Female subjects are considered of childbearing potential unless they are postmenopausal (absence of menstrual bleeding for 1 year - or 6 months if laboratory confirmation o
研究者
相似试验
进行中（未招募）
2 期
Testing new medicine for adults with Cystic Fibrosis who do not have access to the currently available CFTR-modulating drugs due to genetic mutationsTreatment of Cystic Fibrosis (CF) in patients with CFTR mutations who are responders in the organoid assayGenetic DiseasesISRCTN96750019niversity Medical Center Utrecht52
进行中（未招募）
1 期
Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseEUCTR2014-001295-65-ATTxCell170
进行中（未招募）
1 期
Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseModerately to severely active Crohn's DiseaseMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2014-001295-65-BETxCell117
进行中（未招募）
1 期
Phase II study evaluating Ovasave, a cell therapy, in patient with active Crohn's DiseaseEUCTR2014-001295-65-DETxCell170
进行中（未招募）
2 期
A clinical trial of 5 mg psilocybin plus psychological support vs 25 mg psilocybin plus psychological support in adults with generalised anxiety disorderGeneralised anxiety disorderMental and Behavioural DisordersISRCTN14487299Incannex Healthcare Limited96